An interventional study of RAA pacing and PSB pacing in Pacing Therapy and Cardiac Pacing, sponsored by Shanghai Tong Ren Hospital. Recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Shanghai Tong Ren Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate whether posterosuperior bundle (PSB) pacing reduces the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND) undergoing pacemaker implantation. Approximately 300 patients will be enrolled and randomized to receive atrial pacing at either the PSB region or the right atrial appendage (RAA). The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes, as detected by device or surface electrocardiogram. Patients will be followed for up to 24 months.
Sinus node dysfunction (SND) is a common indication for permanent pacemaker implantation. Conventional right atrial appendage (RAA) pacing may result in delayed or dyssynchronous atrial activation, potentially increasing the risk of atrial arrhythmias. Posterosuperior bundle (PSB) pacing is a novel physiological atrial pacing approach. This study is a prospective, multicenter, open-label, randomized controlled trial. A total of approximately 300 eligible SND patients indicated for pacemaker implantation will be enrolled and randomly assigned (1:1) to PSB pacing or RAA pacing. Ventricular pacing will be performed using left bundle branch area pacing in both groups. Following implantation, the pacemaker will be programmed in DDD mode with a lower rate of 70 beats/min during daytime and 60 beats/min during nighttime. Rate-responsive pacing will be enabled by default when available; ATP will be disabled by default. Participants will be followed at 3, 6, 12, and 24 months after implantation. The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes. Secondary endpoints include atrial high-rate episodes, AF burden, pacing parameters, ECG and echocardiographic indices, laboratory findings, and mortality outcomes. Safety endpoints include procedural complications and device-related adverse events.
Shanghai Tong Ren Hospital is the lead sponsor of 17 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients were randomly assigned to receive posterosuperior bundle pacing for atrial pacing during regular pacemaker implantation procedures.
Procedure: PSB pacing
Patients were randomly assigned to receive right atrial appendage pacing for atrial pacing during regular pacemaker implantation procedures.
Procedure: RAA pacing
Atrial pacing lead implanted at the right atrial appendage. Left bundle branch area pacing will be applied if ventricular pacing is necessary.
Atrial pacing lead implanted at the posterosuperior bundle region. Left bundle branch area pacing will be applied if ventricular pacing is necessary.
Incidence of atrial fibrillation
Incidence of atrial fibrillation ≥ 6 minutes during follow-ups
Time frame: From implantation to regular follow-ups up to 24 months
Atrial high-rate episodes
Time frame: From implantation to regular follow-ups up to 24 months
AF burden
Time frame: From implantation to regular follow-ups up to 24 months
Intrinsic P-wave duration
Measured from the onset of the P wave to the end
Time frame: At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable
Paced P-wave duration
Measured from the pacing stimulus to P wave end duration
Time frame: From implantation to regular follow-ups up to 24 months
Left ventricular ejection fraction (LVEF)
Standard transthoracic echocardiographic parameter
Time frame: At baseline, 6-, 12-, and 24-month follow-ups
Left atrial diameter (LAD)
Standard transthoracic echocardiographic parameter
Time frame: At baseline, 6-, 12-, and 24-month follow-ups
Right atrial diameter (RAD)
Standard transthoracic echocardiographic parameter
Time frame: At baseline, 6-, 12-, and 24-month follow-ups
Left ventricular end-systolic diameter (LVESD)
Standard transthoracic echocardiographic parameter
Time frame: At baseline, 6-, 12-, and 24-month follow-ups
Left ventricular end-diastolic diameter (LVEDD)
Standard transthoracic echocardiographic parameter
Time frame: At baseline, 6-, 12-, and 24-month follow-ups
E/e'
Standard transthoracic echocardiographic parameter
Time frame: At baseline, 6-, 12- , 24-month follow-ups
Mitral regurgitation severity
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe)
Time frame: At baseline, 6-, 12- , 24-month follow ups
Tricuspid regurgitation severity
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe)
Time frame: At baseline, 6-, 12-, 24- month follow-ups
NT-pro BNP
Standard transthoracic echocardiographic parameter
Time frame: At baseline, before discharge, and 6-month follow-up
eGFR
Time frame: At baseline, before discharge, and 6 - month follow-up
All-cause mortality
Time frame: From implantation to regular follow-ups up to 24 months
Cardiovascular death
Time frame: From implantation to regular follow-ups up to 24 months
Procedural complications
Safety Outcome
Time frame: Perioperative
Postoperative adverse events
Safety Outcome, including lead-related complications, thromboembolic events, etc.
Time frame: From implantation to regular follow-ups up to 24 months
Atrial pacing capture threshold
Time frame: From implantation to regular follow-ups up to 24 months
Atrial sensing amplitude
Time frame: From implantation to regular follow-ups up to 24 months
Atrial pacing output
Time frame: From implantation to regular follow-ups up to 24 months
Paced P-wave morphology
positive, negative, notched, and biphasic
Time frame: From implantation to regular follow-ups up to 24 months
Intrinsic P-wave morphology
positive, negative, notched, and biphasic
Time frame: At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Feb 2029, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Tong Ren Hospital